MAPK1 and breast carcinoma: Activated (phosphorylated) ERK (pERK) has been reported to be a prognostically relevant tumor-specific biomarker in breast cancer and to date, there is a controversy whether activated ERK signaling in tumor cells is associated with better [7] or worse [8], [9] relapse-free survival.